Drug intelligence / Profile preview

SolGlo

Development stage: Unknown
Lead developer: Emcutix Biopharmaceuticals
Modality: Small Molecules
Administration: Topical

Overview

SolGlo is a topical broad-spectrum sunscreen formulation developed and marketed by Emcutix Biopharmaceuticals, a subsidiary of Emcure Pharmaceuticals. It is designed to protect the skin from the harmful effects of ultraviolet (UV) radiation, including sunburn, premature skin aging (photoaging), and hyperpigmentation. The product typically utilizes a combination of chemical UV filters and physical blockers to absorb or reflect UVA and UVB rays. SolGlo is part of Emcutix's commercial dermatology portfolio, which focuses on providing prescription and consumer skincare solutions for various dermatologic conditions.

Brand names: SolGlo

Beyond the preview

Go deeper on SolGlo.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SolGlo.

Explore the full profile